COVID-19大流行前两年体外膜氧合结局的演变:系统综述与荟萃分析
该研究为系统综述与荟萃分析(CRD42021271202),检索MEDLINE、Embase、Cochrane和Scopus数据库2019年12月1日至2022年1月26日的研究,纳入52项研究共18,211例接受ECMO的COVID-19成人患者。合并死亡率为48.8%(95%CI 44.8-52.9%,高确定性);随入组时间推移死亡率升高:2020年上半年41.2%、2020年下半年46.4%、2021年上半年62.0%、2021年下半年46.5%(交互作用P=0.0014)。年龄、最后1例患者入组时间距2020年1月1日的时长、接受皮质类固醇的患者比例以及ECMO运行时间缩短是死亡率升高的预测因素。作者认为死亡原因可能为多因素,启动ECMO决策应包含启动时对死亡率的 contextual 估计。
要点
- 接受ECMO的COVID-19成人患者合并死亡率为48.8%(95%CI 44.8-52.9%,高确定性)。
- 死亡率随大流行阶段变化:2020年上半年41.2%、2020年下半年46.4%、2021年上半年62.0%、2021年下半年46.5%(交互作用P=0.0014)。
- 死亡率升高的预测因素包括年龄、最后1例患者入组时间距2020年1月1日的时长、接受皮质类固醇的患者比例以及ECMO运行时间缩短。
- 作者认为启动ECMO的决策应包含启动时对死亡率的 contextual 估计。
适用人群与场景
- 接受ECMO的COVID-19成人患者。
研究设计与关键结果
- 研究类型为系统综述与荟萃分析(CRD42021271202),检索MEDLINE、Embase、Cochrane和Scopus数据库2019年12月1日至2022年1月26日,纳入52项研究共18,211例接受ECMO的COVID-19成人患者。
- 合并死亡率为48.8%(95%CI 44.8-52.9%,高确定性)。
- 按入组时间分层死亡率:2020年上半年41.2%,2020年下半年46.4%,2021年上半年62.0%,2021年下半年46.5%,交互作用P=0.0014。
- 死亡率升高的预测因素包括年龄、最后1例患者入组时间距2020年1月1日的时长、接受皮质类固醇的患者比例以及ECMO运行时间缩短。
证据类型、等级与局限
- 证据类型为系统综述与荟萃分析,采用GRADE方法评估合并估计的确定性,合并死亡率为高确定性。
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为,随着这些患者结局的演变,启动ECMO的决策应包含启动时对死亡率的 contextual 估计。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Extracorporeal membrane oxygenation (ECMO) has been used extensively for coronavirus disease 2019 (COVID-19)-related acute respiratory distress syndrome (ARDS). Reports early in the pandemic suggested that mortality in patients with COVID-19 receiving ECMO was comparable to non-COVID-19-related ARDS. However, subsequent reports suggested that mortality appeared to be increasing over time. Therefore, we conducted an updated systematic review and meta-analysis, to characterise changes in mortality over time and elucidate risk factors for poor outcomes.
METHODS: We conducted a meta-analysis (CRD42021271202), searching MEDLINE, Embase, Cochrane, and Scopus databases, from 1 December 2019 to 26 January 2022, for studies reporting on mortality among adults with COVID-19 receiving ECMO. We also captured hospital and intensive care unit lengths of stay, duration of mechanical ventilation and ECMO, as well as complications of ECMO. We conducted random-effects meta-analyses, assessed risk of bias of included studies using the Joanna Briggs Institute checklist and evaluated certainty of pooled estimates using GRADE methodology.
RESULTS: Of 4522 citations, we included 52 studies comprising 18,211 patients in the meta-analysis. The pooled mortality rate among patients with COVID-19 requiring ECMO was 48.8% (95% confidence interval 44.8-52.9%, high certainty). Mortality was higher among studies which enrolled patients later in the pandemic as opposed to earlier (1st half 2020: 41.2%, 2nd half 2020: 46.4%, 1st half 2021: 62.0%, 2nd half 2021: 46.5%, interaction p value = 0.0014). Predictors of increased mortality included age, the time of final patient enrolment from 1 January 2020, and the proportion of patients receiving corticosteroids, and reduced duration of ECMO run.
CONCLUSIONS: The mortality rate for patients receiving ECMO for COVID-19-related ARDS has increased as the pandemic has progressed. The reasons for this are likely multifactorial; however, as outcomes for these patients evolve, the decision to initiate ECMO should include the best contextual estimate of mortality at the time of ECMO initiation.
参考来源
- Ling RR, Ramanathan K, Sim JJL, et al. Evolving outcomes of extracorporeal membrane oxygenation during the first 2 years of the COVID-19 pandemic: a systematic review and meta-analysis. Crit Care. 2022. PMID: 35606884. doi:10.1186/s13054-022-04011-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。